Abstract: The technology described herein is directed towards runtime dynamic downlink power configuration between a distributed unit and radio unit. In one O-RAN-compliant implementation, control-plane messages are used to update the downlink power without any service interruption, based on initialization information provided by management-plane messages to the distributed unit, including a radio unit's indication of support for the power change and the time (gap) needed by the radio unit to implement a power change. Based on this data, the distributed unit and radio unit (which are synchronized) change the downlink power at the same specific time (same symbol) such that the power configuration can be done during runtime without any service interruption. This is advantageous with power changes needed for Citizens Broadband Radio Service (CBRS) systems and/or for energy saving purposes, for example.

Abstract: Provided are Cas12i polypeptides, fusion proteins comprising such Cas12i polypeptides, CRISPR-Cas12i systems comprising such Cas12i polypeptides or fusion proteins, and methods of using the same.

Abstract: Radio unit equipment that facilitates radio unit time alignment and delay characterization includes a buffer that stores input data received via a signal ingress point of the radio unit equipment, resulting in buffered data. The radio unit equipment also includes clock generation logic that provides a synchronized frame number (SFN) pulse to the buffer. The buffer releases the buffered data at a time corresponding to the SFN pulse and modified by a timing adjustment parameter, resulting in the buffered data proceeding from the buffer to a signal egress point of the radio unit equipment. Additionally, the buffer determines the timing adjustment parameter based on a defined signal propagation delay between the buffer and the signal egress point of the radio unit equipment.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: The described technology is generally directed towards interoperability between distributed units (DUs) and radio units (RUs) in a radio access network (RAN) network. Various embodiments are presented to enable automated determination and/or automated implementation of various configurations and functionalities on a physical random access channel (PRACH) between a DU and a RU. The automated operations presented herein enable a DU to discover and verify PRACH functionality (e.g., regarding PRACH time offset) supported by a RU and/or implementation of the PRACH functionality at the RU to enable interoperability between the DU and the RU, thereby satisfying the interoperability requirement of the O-RAN specification.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: A socket connector includes a base formed of a conductive upper base part and a conductive lower base part which are affixed together, a conductive barrel seated within a passageway and a pocket formed by the base, at least one conductive biasing member engaging the base and the barrel, a conductive contact seated within the barrel, and an insulative housing in which the base is positioned. The housing is coupled to the base. At least one of the upper and lower base parts has a plurality of pins depending from the respective wall which seat within plated through holes of a printed circuit board. A coupling pin is mounted in the socket connector and is further coupled to an electrical component.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: A compound, an organic electroluminescent device containing the compound, and an application thereof. The compound has a structure shown in (I).

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.